SG11201503438PA - Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients - Google Patents
Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patientsInfo
- Publication number
- SG11201503438PA SG11201503438PA SG11201503438PA SG11201503438PA SG11201503438PA SG 11201503438P A SG11201503438P A SG 11201503438PA SG 11201503438P A SG11201503438P A SG 11201503438PA SG 11201503438P A SG11201503438P A SG 11201503438PA SG 11201503438P A SG11201503438P A SG 11201503438PA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- effect
- cancer patients
- hepatocellular carcinoma
- clinical outcome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG11201503438PA SG11201503438PA (en) | 2012-10-30 | 2013-10-30 | Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG2012080248 | 2012-10-30 | ||
| PCT/SG2013/000469 WO2014070114A1 (en) | 2012-10-30 | 2013-10-30 | Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients |
| SG11201503438PA SG11201503438PA (en) | 2012-10-30 | 2013-10-30 | Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503438PA true SG11201503438PA (en) | 2015-06-29 |
Family
ID=53951170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503438PA SG11201503438PA (en) | 2012-10-30 | 2013-10-30 | Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9988694B2 (en) |
| EP (1) | EP2914751A4 (en) |
| CN (1) | CN104884636B (en) |
| SG (1) | SG11201503438PA (en) |
| WO (1) | WO2014070114A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104884636B (en) | 2012-10-30 | 2018-09-18 | 新加坡科技研究局 | Influences of the HBV to hepatocellular carcinoma cancer patient's clinical effectiveness |
| WO2020023887A1 (en) * | 2018-07-27 | 2020-01-30 | Seekin, Inc. | Hepatocellular carcinoma screening |
| EP4022086A1 (en) | 2019-08-27 | 2022-07-06 | F. Hoffmann-La Roche AG | Compositions and methods for amplification and detection of hepatitis b virus rna, including hbv rna transcribed from cccdna |
| WO2022039299A1 (en) * | 2020-08-20 | 2022-02-24 | 경상대학교병원 | Information provision method for predicting survival rate of patient with hepatocellular carcinoma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072185A1 (en) * | 2000-09-15 | 2004-04-15 | Patrizia Paterlini-Brechot | Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses |
| CA2557761A1 (en) * | 2004-03-05 | 2005-09-15 | Otsuka Pharmaceutical Co., Ltd. | Method of detecting carcinogenesis caused by hepatitis b virus |
| US20060057670A1 (en) * | 2004-09-10 | 2006-03-16 | The Chinese University Of Hong Kong | Genomic markers of hepatitis B virus associated with hepatocellular carcinomas |
| CN104884636B (en) | 2012-10-30 | 2018-09-18 | 新加坡科技研究局 | Influences of the HBV to hepatocellular carcinoma cancer patient's clinical effectiveness |
-
2013
- 2013-10-30 CN CN201380068152.9A patent/CN104884636B/en not_active Expired - Fee Related
- 2013-10-30 US US14/439,967 patent/US9988694B2/en not_active Expired - Fee Related
- 2013-10-30 SG SG11201503438PA patent/SG11201503438PA/en unknown
- 2013-10-30 EP EP13851719.8A patent/EP2914751A4/en not_active Withdrawn
- 2013-10-30 WO PCT/SG2013/000469 patent/WO2014070114A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP2914751A4 (en) | 2016-06-01 |
| US20150275317A1 (en) | 2015-10-01 |
| CN104884636A (en) | 2015-09-02 |
| WO2014070114A1 (en) | 2014-05-08 |
| US9988694B2 (en) | 2018-06-05 |
| EP2914751A1 (en) | 2015-09-09 |
| CN104884636B (en) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212926A1 (en) | Methods of treatment of hepatocellular carcinoma | |
| HK1232158A1 (en) | Medicament for treatment of liver cancer | |
| HRP20190046T1 (en) | Combination therapy for the treatment of cancer | |
| HK1209456A1 (en) | Oligonucleotide for the treatment of muscular dystrophy patients | |
| HK1218078A1 (en) | Drug for treatment of nonalcoholic fatty liver disease | |
| EP2830633A4 (en) | Combination therapy for the treatment of cancer | |
| HK1214128A1 (en) | Treatment of cancer | |
| HK1210788A1 (en) | Therapeutic biologic for treatment of hepatocellular carcinoma | |
| HK1206611A1 (en) | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients (hcc) | |
| HK1215000A1 (en) | Treatment and diagnosis of colon cancer | |
| HK1204956A1 (en) | Treatment of cancer | |
| GB201217892D0 (en) | Treatment of cancer | |
| IL275636A (en) | Therapeutic combination for the treatment of cancer | |
| SG11201503438PA (en) | Effect of hbv on clinical outcome of hepatocellular carcinoma cancer patients | |
| SI2892925T1 (en) | Combination treatment of cancer | |
| PL2855475T3 (en) | Alpha-carbolines for the treatment of cancer | |
| GB201217890D0 (en) | Treatment of cancer | |
| IL233495A0 (en) | Combination therapy for the treatment of cancer | |
| GB201219092D0 (en) | Treatment of cardiovascular disease | |
| GB201208296D0 (en) | Treatment of cancer | |
| GB201222950D0 (en) | Combination treatment of cancer | |
| GB201222949D0 (en) | Combination Treatment of Cancer | |
| IL204097A0 (en) | Medicine for the treatment of skin cancer | |
| GB201204645D0 (en) | Treatment of disease |